Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.76 USD | -1.36% | +5.58% | +51.32% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 12.37M | Capitalization | 1.66B |
---|---|---|---|---|---|
Net income 2024 * | -217M | Net income 2025 * | -236M | EV / Sales 2024 * | - |
Net cash position 2024 * | 370M | Net cash position 2025 * | - | EV / Sales 2025 * | 134 x |
P/E ratio 2024 * |
-8.57
x | P/E ratio 2025 * |
-8.35
x | Employees | 142 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.5% |
Latest transcript on Kura Oncology, Inc.
1 day | -1.36% | ||
1 week | +5.58% | ||
Current month | +5.58% | ||
1 month | +3.27% | ||
3 months | -2.25% | ||
6 months | +92.57% | ||
Current year | +51.32% |
Managers | Title | Age | Since |
---|---|---|---|
Troy Wilson
CEO | Chief Executive Officer | 55 | 14-08-21 |
Stephen Dale
CTO | Chief Tech/Sci/R&D Officer | 52 | 20-08-24 |
Kathleen Ford
COO | Chief Operating Officer | 77 | 19-08-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 21-06-02 |
Faheem Hasnain
BRD | Director/Board Member | 65 | 15-04-26 |
Thomas Malley
BRD | Director/Board Member | 55 | 15-10-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - | |
0.05% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 21.76 | -1.36% | 937,639 |
24-06-06 | 22.06 | +1.24% | 854,495 |
24-06-05 | 21.79 | +4.81% | 424,628 |
24-06-04 | 20.79 | -1.89% | 588,489 |
24-06-03 | 21.19 | +2.81% | 671,247 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.32% | 1.66B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- KURA Stock